A Powerful Yeast Model to Investigate the Synergistic Interaction of α-Synuclein and Tau in Neurodegeneration

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Ciaccioli, Gianmario ^a   Martins, Ana ^a   Rodrigues, Cátia ^a   Vieira, Helena ^a   Calado, Patrícia ^a  

^a UNIVERSITY OF LISBON   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; GLYCOGEN SYNTHASE KINASE 3BETA; ISOPROTEIN; MUTANT PROTEIN; PROTEIN SERINE THREONINE KINASE; SERINE; TAU PROTEIN;

ARTICLE; BIOLOGICAL MODEL; CONTROLLED STUDY; GENOME ANALYSIS; NERVE DEGENERATION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SACCHAROMYCES CEREVISIAE; SIGNAL TRANSDUCTION; WILD TYPE; YEAST;

ALPHA-SYNUCLEIN; NEURODEGENERATIVE DISEASES; PROTEIN BINDING; TAU PROTEINS;

EID: 84873517075     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0055848     Document Type: Article

References (74)

1. Esposito A, Dohm CP, Kermer P, Bahr M, Wouters FS, (2007) alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton. Neurobiol Dis 26: 521-531.
2. Popescu A, Lippa CF, Lee VM, Trojanowski JQ, (2004) Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions. Arch Neurol 61: 1915-1919.
3. Trotta L, Guella I, Solda G, Sironi F, Tesei S, et al. (2012) SNCA and MAPT genes: Independent and joint effects in Parkinson disease in the Italian population. Parkinsonism Relat Disord 18: 257-262.
4. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, et al. (1997) Alpha-synuclein in Lewy bodies. Nature 388: 839-840.
5. Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP, (1995) Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry 58: 160-166.
6. Stefanis L, (2012) alpha-Synuclein in Parkinson's Disease. Cold Spring Harb Perspect Med 2: a009399.
7. Marti MJ, Tolosa E, Campdelacreu J, (2003) Clinical overview of the synucleinopathies. Mov Disord 18Suppl 6: S21-27.
8. Bekris LM, Mata IF, Zabetian CP, (2010) The genetics of Parkinson disease. J Geriatr Psychiatry Neurol 23: 228-242.
9. Sellbach AN, Boyle RS, Silburn PA, Mellick GD, (2006) Parkinson's disease and family history. Parkinsonism Relat Disord 12: 399-409.
10. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, et al. (2004) Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
11. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, et al. (2003) alpha-Synuclein locus triplication causes Parkinson's disease. Science 302: 841.
12. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, et al. (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
13. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, et al. (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276: 2045-2047.
14. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, et al. (2004) The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55: 164-173.
15. Kosik KS, Joachim CL, Selkoe DJ, (1986) Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci U S A 83: 4044-4048.
16. Grundke-Iqbal I, Iqbal K, Quinlan M, Tung YC, Zaidi MS, et al. (1986) Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J Biol Chem 261: 6084-6089.
17. Karakaya T, Fusser F, Prvulovic D, Hampel H, (2012) Treatment Options for Tauopathies. Curr Treat Options Neurol 14: 126-136.
18. Kremer A, Louis JV, Jaworski T, Van Leuven F, (2011) GSK3 and Alzheimer's Disease: Facts and Fiction. Front Mol Neurosci 4: 17.
19. Pritchard SM, Dolan PJ, Vitkus A, Johnson GV, (2011) The toxicity of tau in Alzheimer disease: turnover, targets and potential therapeutics. J Cell Mol Med 15: 1621-1635.
20. Hanger DP, Anderton BH, Noble W, (2009) Tau phosphorylation: the therapeutic challenge for neurodegenerative disease. Trends Mol Med 15: 112-119.
21. Kimura T, Fukuda T, Sahara N, Yamashita S, Murayama M, et al. (2010) Aggregation of detergent-insoluble tau is involved in neuronal loss but not in synaptic loss. J Biol Chem 285: 38692-38699.
22. Goedert M, Spillantini MG, (2000) Tau mutations in frontotemporal dementia FTDP-17 and their relevance for Alzheimer's disease. Biochim Biophys Acta 1502: 110-121.
23. Elbaz A, Ross OA, Ioannidis JP, Soto-Ortolaza AI, Moisan F, et al. (2011) Independent and joint effects of the MAPT and SNCA genes in Parkinson disease. Ann Neurol 69: 778-792.
24. Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, et al. (2009) Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol 117: 151-158.
25. Giasson BI, Lee VM, Trojanowski JQ, (2003) Interactions of amyloidogenic proteins. Neuromolecular Med 4: 49-58.
26. Muntane G, Dalfo E, Martinez A, Ferrer I, (2008) Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Neuroscience 152: 913-923.
27. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, et al. (2003) Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300: 636-640.
28. Benussi L, Ghidoni R, Paterlini A, Nicosia F, Alberici AC, et al. (2005) Interaction between tau and alpha-synuclein proteins is impaired in the presence of P301L tau mutation. Exp Cell Res 308: 78-84.
29. Jensen PH, Hager H, Nielsen MS, Hojrup P, Gliemann J, et al. (1999) alpha-synuclein binds to Tau and stimulates the protein kinase A-catalyzed tau phosphorylation of serine residues 262 and 356. J Biol Chem 274: 25481-25489.
30. Duka T, Rusnak M, Drolet RE, Duka V, Wersinger C, et al. (2006) Alpha-synuclein induces hyperphosphorylation of Tau in the MPTP model of parkinsonism. FASEB J 20: 2302-2312.
31. Waxman EA, Giasson BI, (2011) Induction of intracellular tau aggregation is promoted by alpha-synuclein seeds and provides novel insights into the hyperphosphorylation of tau. J Neurosci 31: 7604-7618.
32. Frasier M, Walzer M, McCarthy L, Magnuson D, Lee JM, et al. (2005) Tau phosphorylation increases in symptomatic mice overexpressing A30P alpha-synuclein. Exp Neurol 192: 274-287.
33. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, et al. (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316: 750-754.
34. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, et al. (2010) Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell 142: 387-397.
35. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, et al. (2011) Amyloid-beta/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci 31: 700-711.
36. Morris M, Koyama A, Masliah E, Mucke L, (2011) Tau reduction does not prevent motor deficits in two mouse models of Parkinson's disease. PLoS One 6: e29257.
37. Lin CH, Tsai PI, Wu RM, Chien CT, (2010) LRRK2 G2019S mutation induces dendrite degeneration through mislocalization and phosphorylation of tau by recruiting autoactivated GSK3ss. J Neurosci 30: 13138-13149.
38. De Vos A, Anandhakumar J, Van den Brande J, Verduyckt M, Franssens V, et al. (2011) Yeast as a model system to study tau biology. Int J Alzheimers Dis 2011: 428970.
39. Franssens V, Boelen E, Anandhakumar J, Vanhelmont T, Buttner S, et al. (2010) Yeast unfolds the road map toward alpha-synuclein-induced cell death. Cell Death Differ 17: 746-753.
40. Outeiro TF, Lindquist S, (2003) Yeast cells provide insight into alpha-synuclein biology and pathobiology. Science 302: 1772-1775.
41. Griffioen G, Duhamel H, Van Damme N, Pellens K, Zabrocki P, et al. (2006) A yeast-based model of alpha-synucleinopathy identifies compounds with therapeutic potential. Biochim Biophys Acta 1762: 312-318.
42. Vandebroek T, Terwel D, Vanhelmont T, Gysemans M, Van Haesendonck C, et al. (2006) Microtubule binding and clustering of human Tau-4R and Tau-P301L proteins isolated from yeast deficient in orthologues of glycogen synthase kinase-3beta or cdk5. J Biol Chem 281: 25388-25397.
43. Vanhelmont T, Vandebroek T, De Vos A, Terwel D, Lemaire K, et al. (2010) Serine-409 phosphorylation and oxidative damage define aggregation of human protein tau in yeast. FEMS Yeast Res 10: 992-1005.
44. Zabrocki P, Pellens K, Vanhelmont T, Vandebroek T, Griffioen G, et al. (2005) Characterization of alpha-synuclein aggregation and synergistic toxicity with protein tau in yeast. FEBS J 272: 1386-1400.
45. Jasnos L, Korona R, (2007) Epistatic buffering of fitness loss in yeast double deletion strains. Nat Genet 39: 550-554.
46. Ito H, Fukuda Y, Murata K, Kimura A, (1983) Transformation of intact yeast cells treated with alkali cations. J Bacteriol 153: 163-168.
47. Girish V, Vijayalakshmi A, (2004) Affordable image analysis using NIH Image/ImageJ. Indian J Cancer 41: 47.
48. Flower TR, Chesnokova LS, Froelich CA, Dixon C, Witt SN, (2005) Heat shock prevents alpha-synuclein-induced apoptosis in a yeast model of Parkinson's disease. J Mol Biol 351: 1081-1100.
49. Fushimi K, Long C, Jayaram N, Chen X, Li L, et al. (2011) Expression of human FUS/TLS in yeast leads to protein aggregation and cytotoxicity, recapitulating key features of FUS proteinopathy. Protein Cell 2: 141-149.
50. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
51. Kimura Y, Koitabashi S, Fujita T, (2003) Analysis of yeast prion aggregates with amyloid-staining compound in vivo. Cell Struct Funct 28: 187-193.
52. Badiola N, de Oliveira RM, Herrera F, Guardia-Laguarta C, Goncalves SA, et al. (2011) Tau enhances alpha-synuclein aggregation and toxicity in cellular models of synucleinopathy. PLoS One 6: e26609.
53. Klucken J, Ingelsson M, Shin Y, Irizarry MC, Hedley-Whyte ET, et al. (2006) Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. Acta Neuropathol 111: 101-108.
54. Ferrer I, Hernandez I, Boada M, Llorente A, Rey MJ, et al. (2003) Primary progressive aphasia as the initial manifestation of corticobasal degeneration and unusual tauopathies. Acta Neuropathol 106: 419-435.
55. Ando K, Leroy K, Heraud C, Yilmaz Z, Authelet M, et al. (2011) Accelerated human mutant tau aggregation by knocking out murine tau in a transgenic mouse model. Am J Pathol 178: 803-816.
56. Ko LW, Ko HH, Lin WL, Kulathingal JG, Yen SH, (2008) Aggregates assembled from overexpression of wild-type alpha-synuclein are not toxic to human neuronal cells. J Neuropathol Exp Neurol 67: 1084-1096.
57. Bancher C, Brunner C, Lassmann H, Budka H, Jellinger K, et al. (1989) Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 477: 90-99.
58. Luna-Munoz J, Chavez-Macias L, Garcia-Sierra F, Mena R, (2007) Earliest stages of tau conformational changes are related to the appearance of a sequence of specific phospho-dependent tau epitopes in Alzheimer's disease. J Alzheimers Dis 12: 365-375.
59. Buee-Scherrer V, Condamines O, Mourton-Gilles C, Jakes R, Goedert M, et al. (1996) AD2, a phosphorylation-dependent monoclonal antibody directed against tau proteins found in Alzheimer's disease. Brain Res Mol Brain Res 39: 79-88.
60. Kassir Y, Rubin-Bejerano I, Mandel-Gutfreund Y, (2006) The Saccharomyces cerevisiae GSK-3 beta homologs. Curr Drug Targets 7: 1455-1465.
61. Kawakami F, Suzuki M, Shimada N, Kagiya G, Ohta E, et al. (2011) Stimulatory effect of alpha-synuclein on the tau-phosphorylation by GSK-3beta. FEBS J 278: 4895-4904.
62. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, et al. (2010) Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 225: 210-218.
63. Wills J, Credle J, Haggerty T, Lee JH, Oaks AW, et al. (2011) Tauopathic changes in the striatum of A53T alpha-synuclein mutant mouse model of Parkinson's disease. PLoS One 6: e17953.
64. Lei P, Ayton S, Finkelstein DI, Adlard PA, Masters CL, et al. (2010) Tau protein: relevance to Parkinson's disease. Int J Biochem Cell Biol 42: 1775-1778.
65. Spittaels K, Van den Haute C, Van Dorpe J, Bruynseels K, Vandezande K, et al. (1999) Prominent axonopathy in the brain and spinal cord of transgenic mice overexpressing four-repeat human tau protein. Am J Pathol 155: 2153-2165.
66. Wittmann CW, Wszolek MF, Shulman JM, Salvaterra PM, Lewis J, et al. (2001) Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science 293: 711-714.
67. Probst A, Gotz J, Wiederhold KH, Tolnay M, Mistl C, et al. (2000) Axonopathy and amyotrophy in mice transgenic for human four-repeat tau protein. Acta Neuropathol 99: 469-481.
68. Andorfer C, Acker CM, Kress Y, Hof PR, Duff K, et al. (2005) Cell-cycle reentry and cell death in transgenic mice expressing nonmutant human tau isoforms. J Neurosci 25: 5446-5454.
69. Spires TL, Orne JD, SantaCruz K, Pitstick R, Carlson GA, et al. (2006) Region-specific dissociation of neuronal loss and neurofibrillary pathology in a mouse model of tauopathy. Am J Pathol 168: 1598-1607.
70. Dixon C, Mathias N, Zweig RM, Davis DA, Gross DS, (2005) Alpha-synuclein targets the plasma membrane via the secretory pathway and induces toxicity in yeast. Genetics 170: 47-59.
71. Veal EA, Ross SJ, Malakasi P, Peacock E, Morgan BA, (2003) Ybp1 is required for the hydrogen peroxide-induced oxidation of the Yap1 transcription factor. J Biol Chem 278: 30896-30904.
72. Kiakos K, Howard TT, Lee M, Hartley JA, McHugh PJ, (2002) Saccharomyces cerevisiae RAD5 influences the excision repair of DNA minor groove adducts. J Biol Chem 277: 44576-44581.
73. Sanders SL, Herskowitz I, (1996) The BUD4 protein of yeast, required for axial budding, is localized to the mother/BUD neck in a cell cycle-dependent manner. J Cell Biol 134: 413-427.
74. Sharma N, Brandis KA, Herrera SK, Johnson BE, Vaidya T, et al. (2006) alpha-Synuclein budding yeast model: toxicity enhanced by impaired proteasome and oxidative stress. J Mol Neurosci 28: 161-178.